SCHEMBL13329014

SCHEMBL13329014

Cc1nc2c(c(=O)n1C(c1ccccc1)c1ccccc1)CN(CCCc1ccccc1)CC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 1/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
GAA P10253 1/20 0.41
ADORA2A P29274 1/20 0.41
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 2/20 0.41
CLPP Q16740 1/20 0.40
SIGMAR1 Q99720 3/20 0.40
PNMT P11086 1/20 0.40
TP53 P04637 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
NFKB1 P19838 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
THPO P40225 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13328991 0.95 CLPP (0.45) CYP1A2CYP2C9GAAADORA2ACLPP
SCHEMBL13328799 0.88 CYP1A2 (0.53) CYP1A2CYP2C9GAAADORA2ACLPP
SCHEMBL13329041 0.85 CYP3A4 (0.39) CYP1A2CYP2C9GAAADORA2ACLPP
SCHEMBL13328834 0.83 CLPP (0.53) CYP1A2CYP2C9GAAADORA2ACLPP
SCHEMBL13329016 0.83 KDM4E (0.39) CYP1A2CYP2C9GAAADORA2ACLPP
SCHEMBL13329001 0.83 CLPP (0.56) CYP1A2CYP2C9GAAADORA2ASLC6A2
SCHEMBL13328816 0.82 CLPP (0.51) CYP1A2CYP2C9GAAADORA2ACLPP
SCHEMBL13329025 0.82 CLPP (0.51) CYP1A2CYP2C9GAAADORA2ACLPP
SCHEMBL13329127 0.82 CLPP (0.48) CYP1A2CYP2C9GAAADORA2ACLPP
SCHEMBL13329017 0.82 CLPP (0.46) CYP1A2CYP2C9GAAADORA2ACLPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318751-B2 Pyrimidinone derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2012-11-27 US disclosed
US-8318751-B2 Pyrimidinone derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2012-11-27 US disclosed
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF GPR119, GPR180, GPR17 HTR5A 212/4885CYP1A2 1604/4885CYP2C9 1570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.